Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1077-28-7
Molecular formula
C8H14O2S2
Molecular weight
206.33 g/mol
Drug class
Mitochondrial enzyme cofactorantioxidant and redox-modulating agent
Mechanism of action
Alpha-lipoic acid is a cofactor for mitochondrial dehydrogenase complexes and can be reduced to dihydrolipoic acid, which participates in redox reactions and antioxidant recycling. It can scavenge reactive oxygen species and influence cellular redox signalling.
Indications / reported uses
Used in some countries for symptomatic treatment of diabetic peripheral neuropathy, including oral and intravenous formulations; indications and authorisation vary by jurisdiction.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Lipoic Acid Environmental Risk Assessment (ERA) (the Lipoic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.